434 articles – 313 references  [version française]
Short view
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism.
Simon T., Beau Yon De Jonage-Canonico M., Oger E., Wahl D., Conard J., Meyer G., Emmerich J., Barrellier M.-T., Guiraud A., Scarabin P.-Y. et al
Journal of Thrombosis and Haemostasis 4, 1 (2006) 71-6 - http://hal.univ-brest.fr/hal-00688975
Life Sciences/Human health and pathology
(16409454)
Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism.
T. Simon1, 2, M. Beau Yon De Jonage-Canonico1, Emmanuel Oger3, Denis Wahl4, Jacqueline Conard5, Guy Meyer6, Joseph Emmerich7, Marie-Thérèse Barrellier8, A. Guiraud1, Pierre-Yves Scarabin () 1,
1:  Epidémiologie cardiovasculaire et métabolique
INSERM : IFR69 – Université Paris XI - Paris Sud
Hôpital Paul Brousse 16, Avenue Paul Vaillant-Couturier 94807 VILLEJUIF CEDEX
France
2:  APHP - DPC - Département de Pharmacologie Clinique
Assistance publique - Hôpitaux de Paris (AP-HP)
Hôpital Saint Antoine PARIS
France
3:  GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
Université de Bretagne Occidentale [UBO]
CHU de la Cavale Blanche Département de médecine interne et pneumologie 29609 BREST
France
4:  DW - Service de Gastro-Entérologie et Hépatologie, Médecine Interne
CHU Nancy
CHRU 29 AV. MAL L. DE TASSIGNY 54000 NANCY
France
5:  JC - UHT - Unité d'hémostase-thrombose
Assistance publique - Hôpitaux de Paris (AP-HP)
Hôtel Dieu PARIS
France
6:  HEGP
Hôpital européen Georges Pompidou
Service de Pneumologie et de Réanimation Médicale
France
7:  Risque Thrombotique et Mecanismes de l'Hemostase
INSERM : U765 – IFR71 – Université Paris V - Paris Descartes
Fac Sc Pharmaceutiques et Biologiques PARIS V 4, Avenue de L'Observatoire 75270 PARIS CEDEX 06
France
8:  Service d'Explorations Fonctionnelles
Hôpital côte de nacre
Caen
France
BACKGROUND: Lifetime estrogen exposure has been related to breast cancer risk, osteoporosis, and cardiovascular disease but data on venous thromboembolism (VTE) risk are limited. METHODS: Data from a hospital-based case-control study among 608 postmenopausal women (191 with a first episode of idiopathic VTE and 417 age-matched controls) were used to determine whether estrogen exposure, as assessed by age at menopause [classified as early (< or = 45 years), normal (46-54 years) and late menopause (> or = 55 years)] and parity, was associated with the risk of VTE. RESULTS: After adjustment for potential confounding variables, the risk of VTE was increased with each year's delay in the menopause [odds ratio (OR) = 1.06, 95% confidence interval (CI) = 1.02-1.10, P < 0.0075]. When compared with women with normal menopause used as a reference, the adjusted OR for VTE was 0.59 (95% CI = 0.36-0.97) and 2.53 (95% CI = 1.28-4.99) for women with early menopause and late menopause, respectively (P = 0.001). Adjusted OR for VTE was also higher for women with more than two children when compared with those with less than or equal to two children (1.56, 95% CI = 1.03-2.34, P = 0.03). The lowest risk of VTE was observed in women with early menopause and lower parity (adjusted OR = 0.60, 95% CI = 0.30-1.24), the highest risk was among women with late menopause who have had more than two children (adjusted OR = 3.41, 95% CI = 1.46-9.25). CONCLUSION: These results show that the longer exposure to endogenous estrogen is associated with an increased VTE risk.
English

Article in peer-reviewed journal
10.1111/j.1538-7836.2005.01693.x
Journal of Thrombosis and Haemostasis (J Thromb Haemost)
Publisher Wiley-Blackwell
ISSN 1538-7933 (eISSN : 1538-7836)
international
2006-01
4
1
71-6

Age Factors – Aged – Case-Control Studies – Estrogens – Female – Humans – Menopause – Middle Aged – Odds Ratio – Parity – Pregnancy – Pulmonary Embolism – Risk – Thromboembolism – Venous Thrombosis